CD8A and neoplasm: This treatment strategy has been successful pre-clinically in a number of other tumor types [26,27,28,29], likely relating to an OV-mediated CD8+ T-cell anti-tumor response and a concomitant up-regulation of tumor PD-L1 expression [30,31].